Study On The Role Of The Signaling Factor P38MAPK On Myocardial Ischemia-Reperfusion Injury

Object:To study the role of the signaling factor of p38MAPK on myocardial Ischemia-Reperfusion Injury based on the animal models, and exploring the relationship between the p38MAPK factor and the cardioprotective effect of p38MAPK inhibitor and Monopril.Methods:SD male rats were divided into five groups randomly (group N:sham group, group A: ischemic 30min, group B:ischemic 30min-reperfusion, group C:Monopril treatment and ischemic 30min-reperfusion, D:p38MAPK inhibitor treatment and ischemic 30min-reperfusion). Inspected the changing of ECG in preparation and operation. Group C was treated with Monopril, Group D was treated with p38MAPK inhibitor, and others was treated with saline. After the operation, determine the levels of myocardial zymogram, and took myocardium to observe the expression about p38MAPK by PCR and immunocytochemistry.Results:1. Myocardium zymogram (include CK and CKMB) in the group B,C and D was significantly higher than the of group N respectively, while goup D and C was lower than that of group B (P< 0.01).2. The gene of p38MAPK in group B was significantly higher than the of group N, while goup D was lower than group B (P< 0.01).3.The expression of p-p38MAPK in the group A,B,C and D was significantly higher than group N respectively, while goup A and D was lower than that of group B (P<0.01)Conclusion:Myocardial Ischemia-Reperfusion can activate p38MAPK signaling transduction path, then reduce Ischemia-Reperfusion Injury. The cardioprotective effect of Monopril to be regard pass the p38MAPK signaling transduction path.